

## STRO-001

STRO-001 is indicated for multiple myeloma. was developed with Sutro's XpressCFTM and XpressCF+TM proprietary cell-free protein synthesis and site-specific conjugation platforms, which enable rapid evaluation of a wide variety of protein structures and design and manufacturing of a highly-optimized single molecular species, rather than the usual mixture of imprecisely conjugated antibodies that comprise an antibody drug conjugate made by conventional cell-based manufacturing.

Preclinical research findings presented by Sutro at the American Society of Hematology's 2017 annual meeting and at other scientific meetings last year highlighted the specificity of STRO-001's anti-CD74 antibody component, the high prevalence of CD74 expression in myeloma and lymphoma tumor samples, STRO-001's potent *in vitro* cytotoxicity in multiple B-cell tumor cell lines and its anti-tumor activity in multiple myeloma and lymphoma xenograft models.

The Phase I clinical trial of STRO-001 is the first clinical trial to be conducted with a product candidate created using cell-free protein synthesis. With the commencement of patient dosing with STRO-001, Sutro Biopharma seeks to establish itself as a leader in cell-free protein synthesis for the discovery and development of cancer therapeutics.

STRO-001 is an antibody-drug conjugate comprised of a human aglycosylated anti-CD74 IgG1 antibody (SP7219) genetically incorporating the non-natural amino acid para-azidomethy-L-phenylalanine (pAMF) to enable the site-specific conjugation of a non-cleavable dibenzocyclooctyne (DBCO)-maytansinoid linker-payload